Novo Nordisk faces a suit claiming it failed to warn users of Ozempic of the danger of blindness. The suit is brought by a ...

A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...

Todd Engel, a Maryland man, is suing Ozempic maker Novo Nordisk after allegedly going blind due to the drug, raising concerns ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...

An elderly American man has become completely blind after he was prescribed to take Ozempic to manage his type 2 diabetes.

The higher risk of developing the sight-threatening eye problem known as nonarteritic anterior ischemic optic neuropathy, or NAION, did not appear during patients’ first year of treatment with ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

More information: Alan Y. Hsu et al, Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.0349 ...

Although only association and not causality can be inferred, this study showed that, among patients who had diabetes, an elevated risk of NAION was associated with semaglutide use compared with ...

Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date. (HealthDay News) — For patients with diabetes, semaglutide use is ...